Drugs / BHV-7000
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07262268 | Jan → Nov 2026 expected | primary erythermalgia | Biohaven Therapeutics Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06423781 | Aug 2024 → Mar 2026 | major depressive disorder | Biohaven Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06443463 | Jul 2024 → Dec 2026 expected | focal epilepsy | Biohaven Therapeutics Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06423794 | Jun 2024 → Apr 2025 | bipolar disorder | Biohaven Therapeutics Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT06419608 | May 2024 → Nov 2025 | major depressive disorder | Biohaven Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT06419582 | May 2024 → Jan 2025 | bipolar disorder | Biohaven Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT06309966 | May 2024 → Oct 2026 expected | focal epilepsy | Biohaven Therapeutics Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06132893 | Mar 2024 → Dec 2026 expected | focal epilepsy | Biohaven Therapeutics Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06425159 Comparator | Jun 2024 → Mar 2026 | generalized epilepsy | Biohaven Therapeutics Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BHV-7000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06309966 ↗ |
| Route | Oral | “Participants will take blinded investigational product (IP) orally once daily” NCT07262268 ↗ |